Royalty Pharma plc vs Abbvie Inc.
RPRX vs ABBV — side-by-side comparison from reported financials. RPRX leads 7, ABBV leads 5 of 12 comparable metrics.
Royalty Pharma plc
RPRX · Healthcare
$56.93+1.28%Solid
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | RPRX | ABBV |
|---|---|---|
| Price | $56.93 | $276.43 |
| Market cap | $25.4B | $488B |
| Revenue (TTM) | $2.54B | $64.4B |
| Revenue growth | +2.1% | +1.8% |
| Net margin | 32.1% | 9.8% |
| Free cash flow | $2.98B | $18.2B |
| Net cash (debt) | ($7.93B) | ($56.2B) |
| 1-year price return | +57.5% | +19.8% |
| P/E | 40.2 | 77.4 |
| P/E vs own history (cheap-side %) | 53% | 23% |
| Dividend yield | 1.22% | 2.45% |
| Return on equity | 12% | 96% |
| Altman Z-score | 2.32 | 2.33 |
| CV checks passed | 10 of 11 | 9 of 11 |
| Employees | 100 | 57,000 |
Full résumé-style profiles: RPRX CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.